Medpace reported strong Q1 earnings, beating estimates but stock dropped 6.4%.

From StockStory Communications: 2025-04-21 16:24:00

Medpace Holdings (NASDAQ:MEDP) reported Q1 CY2025 revenue of $558.6 million, beating analyst estimates by 6% and showing a 9.3% year-on-year growth. The company’s GAAP profit of $3.67 per share was 20.8% above analysts’ expectations. Medpace raised its full-year revenue guidance to $2.19 billion, surpassing estimates by 1.9%. The company’s operating margin remained stable at 20.3%, and its EPS grew to $3.67 in Q1. Despite positive results, Medpace stock dropped 6.4% post-earnings. Investors should analyze valuation and business qualities before considering an investment.

Founded in 1992, Medpace provides clinical trial management and research services in the pharmaceutical, biotechnology, and medical device industries. The company’s revenue growth has been impressive, averaging 17.5% over the last two years. Analysts project flat revenue growth for the next 12 months, indicating potential demand headwinds. Medpace’s operating margin has been stable at 20.3% in Q1, showcasing efficient cost management. The company’s EPS growth and improved profitability highlight strong performance. Investors should assess Medpace’s valuation and business fundamentals before making investment decisions.



Read more at StockStory Communications: Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops